GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH
María Andrés‐Rozas, Jordi Gracia‐Sancho(Institut d'Investigacions Biomèdiques de Barcelona), Juan José Lozano(Instituto de Salud Carlos III), Zoe Boyer‐Díaz, Peio Aristu-Zabalza(Departament de Salut), Jaime Bosch(Instituto de Salud Carlos III), Jaume Mercadé(Highlight Therapeutics (Spain)), Sergi Guixé‐Muntet(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Carla Fuster(Hospital Clínic de Barcelona), Eugènia Ruiz-Cánovas(Highlight Therapeutics (Spain)), Cristina Fernández-Asensio(Highlight Therapeutics (Spain)), Noemı́ Garcı́a-Delgado(Highlight Therapeutics (Spain))
Cited by 2
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
|Clinical Nutrition|2024|44